In March and again in June, Ladenburg Thalmann analyst Michael Higgins gave the stock a $20 price target. Shares of Ovid Therapeutics (NASDAQ: OVID) have more than doubled over the past four months, a performance the clinical-stage biotech company owes in part to a positive rating from an analyst. So it isn't surprising that investors rushed to purchase Ovid's stock, sending shares significantly higher. © 2020 Verizon Media. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. More news: Financials (USD) Sales 2020: 0,17 M--Net income 2020-90,6 M--Net Debt 2020---P/E ratio 2020-3,77x: Yield 2020-Capitalization: 379 M 379 M-Capi. Ovid has a broad pipeline of potential first-in-class medicines. Investors should expect the company will need to resort to dilutive forms of financing before that happens (if it does at all). Is Ovid Therapeutics Stock a Buy? Ovid reported positive results from a phase 2 clinical trial in that indication back in May. In particular, Ovid's OV101 is an investigational treatment for a rare disorder called Angelman syndrome. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Beyond motor seizures, individual CDD patients also demonstrated improvements in other seizure types, as reported previously. “Soticlestat is emerging as a potentially valuable therapeutic option, particularly given its favorable safety profile and potential to provide a durable treatment benefit. Currency in USD, Trade prices are not sourced from all markets, How He Made $2.8M Trading Stocks Part-Time At Home. In March and again in June, Ladenburg Thalmann analyst Michael Higgins gave the stock a $20 price target. / Sales 2021: 81,2x: Nbr of Employees: 60: Free-Float: 65,3%: More Financials. The Ovid Therapeutics Inc stock gained 3.01% in the last trading day (Wednesday, 7th Oct 2020), rising from $5.99 to $6.17. Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com, Investors:Steve KlassBurns McClellan, Inc.sklass@burnsmc.com(212) 213-0006, 2020 GlobeNewswire, Inc., source Press Releases. Volume has increased in the last day along with the price, which is a positive technical sign, and, in total, 322 thousand more shares were traded than the day before. See you at the top! Shares of Ovid Therapeutics (NASDAQ:OVID) have more than doubled over the past four months, a performance the clinical-stage biotech company owes … We have upgraded our analysis conclusion for this stock since last evaluation from a Sell Candidate to a Buy Candidate candidate. Ovid currently has no products on the market and doesn't generate any revenue. Developmental and epileptic encephalopathies typically present early in life and are often associated with severe cognitive and developmental impairment in addition to frequent treatment-resistant seizures throughout the person's lifetime. By using the site you agree and are held During the study, OV101 was found to be generally safe and well-tolerated by Fragile X syndrome patients, and those taking the drug showed a statistically significant improvement in some of their symptoms. In short, investors will want to keep a close eye on this healthcare stock. (This stock has medium daily movements and this gives medium risk. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. While that cash balance seems healthy enough, the company is still at least a couple of years away from launching OV101 on the market. Opthea to Appoint Dr Jeremy Levin as Chairman of the Board, Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in, Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference, Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock, Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet, Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update, Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020, Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of, Ovid Therapeutics Inc.: オービッド･セラピューティクスとアンジェリーニ･ファーマ、アンジェル, How Goldman's Koch Is Positioning Ahead of the Election, 1460 Broadway Patients in the study were allowed to be on one to six concomitant anti-epileptic drugs (AEDs), with the majority of patients concomitantly treated with at least four AEDs, representing a highly refractory patient population. The combined market opportunity for OV101 could be huge -- but only if the FDA approves the drug. The market is probably reacting to Ovid getting a buy rating from an analyst. Kyle Dennis took a leap of faith and decided to invest his savings of $15K in the stock market — $2.8M later, he owes his success to these strategies. Data from Dup15q SyndromeDup15q patients also exhibited a variety of seizures types, including motor (tonic and atonic), myoclonic and absence seizures. These disorders vary in age of onset, developmental outcomes, etiologies, neuropsychological deficits, electroencephalographic (EEG) patterns, seizure types and prognosis. Despite the availability of medicines for epilepsy generally, there are no approved therapies for CDD and Dup15q syndrome. Since then, OVID shares have increased by 117.4% and is now trading at $5.8250. In his free time, you'll find him curling up with a good book or doing math. Tip: Try a valid symbol or a specific company name for relevant results, Singapore markets open in 5 hours 42 minutes, NasdaqGS - NasdaqGS Real Time Price. Data reported today are consistent with, and build upon, previous findings with soticlestat. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Ovid Therapeutics Stock a Buy? The outlook for OV101 seems encouraging given the results from its phase 2 clinical trials in both indications. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. What's more, Higgins gave Ovid a price target of $20, which represents a significant upside from the company's previous close of $5.43. Ovid Therapeutics (OVID) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes. Takeda and Ovid are sharing in the development and commercialization costs of soticlestat on a 50/50 basis, and if successful, the companies will share in the profits on a 50/50 basis. The biotech doesn't have any products on the market at the moment and does not generate any revenue. $5.88 Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time, In CDD patients, median motor seizure frequency reduction was 24% in the ARCADE study, increasing to a 50% reduction in ENDYMION long-term extension study, Clinical Global Impression of Change (CGI-C) and Caregiver Global Impression of Change (Care GI-C) suggest improvements beyond motor seizure frequency reduction in both CDD and Dup15q patients, Soticlestat was generally well tolerated in both studies and continues to demonstrate a favorable safety profile.